{
  "@context": {
    "bsc": "http://bioschemas.org/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@graph": [
    {
      "@id": "https://doi.org/10.1101/731836",
      "@type": "sc:CreativeWork"
    },
    {
      "@id": "https://bio.tools/non-transferability",
      "@type": "sc:SoftwareApplication",
      "sc:applicationSubCategory": [
        {
          "@id": "edam:topic_2640"
        },
        {
          "@id": "edam:topic_0108"
        },
        {
          "@id": "edam:topic_0202"
        }
      ],
      "sc:citation": {
        "@id": "https://doi.org/10.1101/731836"
      },
      "sc:description": "> VERY_LOW CONFIDENCE! | > HOMEPAGE MISSING! | > CORRECT NAME OF TOOL COULD ALSO BE 'response-specific', 'irreproducibility', 'Translational', 'medication' | Methodological Challenges in Translational Drug Response Modeling in Cancer | Abstract Translational models directly relating drug response-specific processes observed in vitro to their in vivo role in cancer patients constitute a crucial part of the development of personalized medication. Unfortunately, ongoing research is often confined by the irreproducibility of the results in other contexts. While the inconsistency of pharmacological data has received great attention recently, the computational aspect of this crisis still deserves closer examination. Notably, studies often focus only on isolated model characteristics instead of examining the overall workflow and the interplay of individual model components. Here, we present a systematic investigation of translational models using the R-package FORESEE",
      "sc:featureList": [
        {
          "@id": "edam:operation_3891"
        },
        {
          "@id": "edam:operation_3501"
        }
      ],
      "sc:name": "non-transferability",
      "sc:url": "https://doi.org/10.1101/731836"
    }
  ]
}